Health Care [ 9/12 ] | Biotechnology [ 43/75 ]
NASDAQ | Common Stock
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca.
Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 26 | 0.00 Increased by +100.00% | -0.01 Increased by +100.00% |
| Mar 19, 26 | -0.01 Increased by +25.00% | -0.01 Decreased by -7.14% |
| Nov 10, 25 | -0.01 Increased by +50.00% | 0.01 Decreased by -175.19% |
| Aug 12, 25 | -0.02 Increased by +76.80% | -0.02 Increased by +17.70% |
| May 23, 25 | -0.02 Increased by +76.37% | -0.01 Decreased by -37.27% |
| Mar 26, 25 | -0.01 Increased by +33.33% | -0.01 |
| Nov 12, 24 | -0.02 Decreased by N/A% | -0.02 |
| Sep 5, 24 | -0.09 Decreased by -331.00% | -0.01 Decreased by -762.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -7.35 M Decreased by -5.31% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -7.02 M Increased by +53.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 500.00 K Increased by +N/A% | -14.62 M Decreased by -19.27% | Decreased by -2.92 K% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -12.89 M Decreased by -43.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.06 M Increased by +6.43% | -6.98 M Increased by +23.37% | Decreased by -655.92% Increased by +27.99% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -15.00 M Decreased by -128.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -12.26 M Decreased by -599.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -8.95 M Decreased by -62.30% | Decreased by N/A% Decreased by N/A% |